Filing Flows › BioCorRx (BICX) › Q2 2026
BioCorRx (BICX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
BioCorRx (BICX) reported revenue of $88K for the second quarter 2026 (Q2 2026), -51% from a year earlier and -59% from the quarter before.
BioCorRx, Q2 2026: revenue $88K (-51% year over year), net loss $1.0M, operating cash flow −$440K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $88K | -59% | -51% |
| Operating profit | −$1.5M | — | — |
| Net earnings | −$1.0M | — | — |
| Operating cash flow | −$440K | — | — |
What changed
Revenue was $88K in Q2 2026, down 51% year over year and down 59% from the previous quarter.
Operating costs exceeded revenue by $1.5M, an operating margin of -1666.0%. Total costs fell 2% while revenue fell 51%. The fastest-growing cost line was Research & development (+140%). The quarter ended with a net loss of $1.0M, narrower than the previous quarter's $1.0M loss. Minority interests bore $37K of it: to shareholders the quarter was a loss of $1.0M. Non-operating items added $464K, -46% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$440K. Non-cash charges added back $10K of depreciation and amortization and $122K of share-based compensation. Working capital and other items added $429K.
Questions
What was BioCorRx's revenue in the second quarter 2026?
BioCorRx (BICX) reported revenue of $88K for the second quarter 2026 (Q2 2026), -51% from a year earlier and -59% from the quarter before.
Source: BioCorRx 10-Q on SEC EDGAR.